Fig. 4.

iC9-CD123.ζ-MC-modified T cells effectively eliminate CD123⁺ leukemia while managing toxicity with iC9. a, b NSG mice were engrafted with CD123⁺ THP-1-EGFPluc tumor cells and subsequently treated with 2.5 × 10⁶ non-transduced (NT) or iC9-CD123.ζ-MC-modified T cells. b Tumor growth was evaluated on a weekly basis using BLI measurements and c 100-day survival was assessed showing a robust and long-term antitumor activity from T cells expressing constitutively active MC compared with iC9-CD19.ζ-modified T cells. d Like CD19-targeted, MC-enhanced CARs, iC9-CD123.ζ-MC-expressing T cells showed similar toxicity in NSG animals, which could be resolved by administration of rimiducid without affecting antitumor activity